Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study Meeting Abstract


Authors: Dietrich, S.; Tilly, H.; Morschhauser, F.; Sehn, L. H.; Friedberg, J. W.; Trněný, M.; Sharman, J.; Herbaux, C.; Burke, J. M.; Matasar, M.; Rai, S.; Izutsu, K.; Mehta-Shah, N.; Oberic, L.; Chauchet, A.; Jurczak, W.; Song, Y. Q.; Greil, R.; Mykhalska, L.; Burgués, J. M. B.; Cheung, M. C.; Pinto, A.; Shin, H. J.; Hapgood, G.; Munhoz, E.; Salles, G.
Abstract Title: Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP ) versus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) therapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from the phase III POLARIX study
Meeting Title: 2022 Deutscher Krebskongress. Krebsmedizin: Schnittstellen zwischen Innovation und Versorgung
Journal Title: Oncology Research and Treatment
Volume: 45
Issue: Suppl. 3
Meeting Dates: 2022 Nov 13-16
Meeting Location: Berlin, Germany
ISSN: 2296-5270
Publisher: S. Karger AG  
Date Published: 2022-11-01
Start Page: 164
Language: English
ACCESSION: WOS:000883051700384
PROVIDER: wos
DOI: 10.1159/000521004
Notes: Meeting Abstract: 891 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Matthew J Matasar
    290 Matasar
  2. Gilles Andre Salles
    272 Salles
Related MSK Work